Urjana Poreci

发表

Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates

S. Milstein, M. Manoharan, S. Chong, 2022, Nature Biotechnology.

Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases.

S. Sheikh, T. Bohnert, P. Schroeder, 2020, Journal of medicinal chemistry.

Expanding the Reach of RNAi Therapeutics with Next Generation Lipophilic siRNA Conjugates

S. Milstein, M. Manoharan, S. Chong, 2021 .

Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy.

K. McCoy, A. Macpherson, B. Julian, 2011, The Journal of clinical investigation.

Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis.

M. Mingueneau, J. Lyssikatos, T. Bohnert, 2021, Journal of medicinal chemistry.

C9ORF72 repeat expansion causes vulnerability of motor neurons to Ca2+-permeable AMPA receptor-mediated excitotoxicity

P. Kind, C. Shaw, Colin Smith, 2018, Nature Communications.

Optimization of novel reversible Bruton's tyrosine kinase inhibitors identified using Tethering-fragment-based screens.

L. Silvian, T. Bohnert, D. Erlanson, 2019, Bioorganic & medicinal chemistry.

Next‐generation Bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cells

M. Mingueneau, Baohong Zhang, S. Belachew, 2021, Clinical & translational immunology.

C9ORF72 repeat expansion causes vulnerability of motor neurons to Ca2+-permeable AMPA receptor-mediated excitotoxicity

P. Kind, C. Shaw, S. Chandran, 2018, Nature Communications.